Reuters logo
3 months ago
BRIEF-Parvus Therapeutics announces license and collaboration agreement of its lead nanomedicine to treat type 1 diabetes
April 19, 2017 / 12:11 PM / 3 months ago

BRIEF-Parvus Therapeutics announces license and collaboration agreement of its lead nanomedicine to treat type 1 diabetes

1 Min Read

April 19 (Reuters) - Novartis Ag

* Parvus therapeutics announces exclusive worldwide license and collaboration agreement for development and commercialization of its lead nanomedicine to treat type 1 diabetes

* Parvus therapeutics says has entered into a license and collaboration agreement with novartis for its lead navacim for treating type 1 diabetes

* Parvus-Under terms,novartis receives exclusive, worldwide rights to use parvus' navacim technology to develop, commercialize products for treatment of type 1 diabetes

* Parvus therapeutics - novartis will be responsible for clinical-stage development and commercialization activities

* Parvus therapeutics says novartis has also made an equity investment in parvus

* Parvus therapeutics - parvus has received an upfront payment and will receive research funding to support preclinical activities Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below